Navigation Links
Three States Sign on to Participate in NABP's Interconnected Prescription Monitoring System
Date:3/22/2011

MOUNT PROSPECT, Ill., March 22, 2011 /PRNewswire-USNewswire/ -- The National Association of Boards of Pharmacy® (NABP®) is pleased to announce that the prescription monitoring programs (PMPs) of North Dakota, Ohio, and Virginia have entered into agreements to participate in the PMP Interconnect™ system, currently under development. PMP Interconnect will allow PMPs across the United States to be linked, providing a more effective means of combating drug diversion and drug abuse nationwide.

PMPs collect prescription data for controlled substances so that physicians and pharmacists can get a complete picture of patients' controlled substance use. Access to this information plays a great role in early detection of prescription abuse and doctor shopping, to allow appropriate intervention and prevention of substance abuse and possible diversion of controlled substances. Current systems, however, lack interoperability and data sharing among states, making these efforts much more difficult to accomplish and making it easier for doctor shoppers to avoid detection by obtaining prescriptions from doctors and pharmacies in multiple states.  

"NABP thanks the North Dakota, Ohio, and Virginia PMPs for being on the forefront of PMP Interconnect with their signing of memorandums of understanding," says NABP President William T. Winsley, MS, RPh. "Participation of PMPs nationwide is a key component of successfully fighting the diversion and abuse of controlled substances. Creating a web of connected PMPs will enhance the benefits of these programs by providing the means for physicians and pharmacists to more easily identify patients with prescription drug problems, especially if that patient is crossing state lines to obtain those drugs."  

In addition, law enforcement and regulatory agencies, where authorized by state law, will be able to obtain information that will help them quickly identify attempts to illegally divert controlled substances across state lines. The PMP Interconnect, which is expected to launch in July 2011, is a highly secure communications exchange platform that will facilitate the transmission of PMP data across state lines to authorized requestors, while ensuring that each state's data access rules are enforced. The PMP Interconnect will not house any data, and the system will not inhibit the legitimate prescribing or dispensing of prescription drugs.

A steering committee made up of PMP administrators that are participating in the PMP Interconnect program will oversee the Interconnect. The PMP Interconnect, which can be utilized by any PMP regardless of where it is housed within the state, will be managed and administered exclusively to support the objectives of the participating PMPs and in support of NABP's mission to assist state boards of pharmacy in creating uniform standards to protect public health.

Understanding current state government funding challenges, NABP has made a commitment to finance the development and deployment of the PMP Interconnect and to fund the annual operating costs of the system for at least the first five years of operation. NABP has the financial resources and stability to provide this funding and will ensure that the PMP Interconnect meets its objectives. The NABP Foundation has received a $1 million grant from Purdue Pharma L.P. to support the deployment of the PMP Interconnect and is also soliciting unrestricted grants from other public and private entities that have a shared interest in enhancing the effectiveness of PMPs.

NABP is the independent, international, and impartial Association that assists its member boards and jurisdictions in developing, implementing, and enforcing uniform standards for the purpose of protecting the public health.


'/>"/>
SOURCE National Association of Boards of Pharmacy
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):